Northwestern Mutual Wealth Management Co. Trims Holdings in Abbott Laboratories $ABT

Northwestern Mutual Wealth Management Co. cut its stake in Abbott Laboratories (NYSE:ABT) by 3.3% in the 4th quarter, according to the company in its most recent disclosure with the SEC. The institutional investor owned 265,706 shares of the healthcare product maker’s stock after selling 9,094 shares during the quarter. Northwestern Mutual Wealth Management Co.’s holdings in Abbott Laboratories were worth $33,290,000 at the end of the most recent quarter.

Several other hedge funds also recently made changes to their positions in ABT. MidAtlantic Capital Management Inc. purchased a new position in shares of Abbott Laboratories in the fourth quarter valued at $25,000. Harbor Capital Advisors Inc. purchased a new position in shares of Abbott Laboratories in the fourth quarter valued at $27,000. Guerra Advisors Inc purchased a new position in shares of Abbott Laboratories in the third quarter valued at $31,000. Bridge Generations Wealth Management LLC purchased a new position in Abbott Laboratories during the third quarter worth about $33,000. Finally, Leonteq Securities AG purchased a new position in Abbott Laboratories during the fourth quarter worth about $35,000. 75.18% of the stock is currently owned by hedge funds and other institutional investors.

Analyst Ratings Changes

Several equities analysts recently commented on the company. Raymond James Financial reduced their target price on Abbott Laboratories from $130.00 to $115.00 and set an “outperform” rating for the company in a research report on Friday, April 17th. Daiwa Securities Group cut shares of Abbott Laboratories from an “outperform” rating to a “neutral” rating and set a $92.00 price objective on the stock. in a research report on Wednesday, April 22nd. Argus dropped their target price on shares of Abbott Laboratories from $140.00 to $125.00 and set a “buy” rating for the company in a research report on Tuesday, April 21st. Piper Sandler cut their price target on shares of Abbott Laboratories from $135.00 to $115.00 and set an “overweight” rating for the company in a research note on Friday, April 17th. Finally, Royal Bank Of Canada lowered their price objective on shares of Abbott Laboratories from $135.00 to $130.00 and set an “outperform” rating on the stock in a research report on Friday, April 17th. Two equities research analysts have rated the stock with a Strong Buy rating, nineteen have assigned a Buy rating and five have given a Hold rating to the company. According to data from MarketBeat.com, the stock currently has a consensus rating of “Moderate Buy” and an average price target of $119.09.

Insider Transactions at Abbott Laboratories

In other news, SVP Eric Shroff sold 709 shares of the company’s stock in a transaction dated Monday, March 2nd. The stock was sold at an average price of $115.58, for a total value of $81,946.22. Following the completion of the transaction, the senior vice president directly owned 39,164 shares in the company, valued at approximately $4,526,575.12. This represents a 1.78% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. Also, EVP Daniel Gesua Sive Salvadori sold 885 shares of the company’s stock in a transaction dated Monday, March 2nd. The stock was sold at an average price of $115.58, for a total value of $102,288.30. Following the completion of the transaction, the executive vice president owned 146,377 shares of the company’s stock, valued at $16,918,253.66. The trade was a 0.60% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. In the last three months, insiders sold 3,055 shares of company stock worth $353,097. Company insiders own 0.46% of the company’s stock.

Abbott Laboratories News Roundup

Here are the key news stories impacting Abbott Laboratories this week:

• Positive Sentiment: Abbott recently secured FDA and EU approval for its AI-powered Ultreon 3.0 tool, which could support growth in its cardiovascular imaging business and add to its medical technology momentum. Article Title
• Positive Sentiment: Abbott also obtained CE mark clearance for its Libre Duo glucose-ketone monitor, expanding its diabetes technology lineup and reinforcing innovation in one of its key growth categories. Article Title
• Neutral Sentiment: Recent coverage highlighting strong Wall Street views on Abbott suggests analysts remain constructive on the stock’s long-term prospects, but the articles do not point to a new upgrade or a near-term earnings catalyst. Article Title
• Neutral Sentiment: Zacks noted that investors have been searching for Abbott more heavily, which can reflect increased interest, but does not by itself change the company’s fundamentals. Article Title
• Negative Sentiment: One comparison piece argued Boston Scientific may offer more upside than Abbott, which can weigh on ABT sentiment by implying investors may prefer a rival medtech name right now. Article Title

Abbott Laboratories Price Performance

ABT opened at $85.36 on Friday. The stock has a 50-day moving average price of $94.46 and a 200-day moving average price of $110.69. Abbott Laboratories has a 12-month low of $81.97 and a 12-month high of $139.06. The company has a current ratio of 1.39, a quick ratio of 1.01 and a debt-to-equity ratio of 0.56. The stock has a market capitalization of $148.68 billion, a P/E ratio of 23.91, a PEG ratio of 1.43 and a beta of 0.65.

Abbott Laboratories (NYSE:ABT) last posted its quarterly earnings data on Thursday, April 16th. The healthcare product maker reported $1.15 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $1.14 by $0.01. Abbott Laboratories had a return on equity of 17.62% and a net margin of 13.90%.The firm had revenue of $11.16 billion during the quarter, compared to analysts’ expectations of $10.99 billion. During the same period in the prior year, the business earned $1.09 EPS. The company’s revenue for the quarter was up 7.8% compared to the same quarter last year. Abbott Laboratories has set its FY 2026 guidance at 5.380-5.580 EPS and its Q2 2026 guidance at 1.250-1.310 EPS. Equities analysts predict that Abbott Laboratories will post 5.48 earnings per share for the current fiscal year.

Abbott Laboratories Company Profile

Abbott Laboratories is a global healthcare company headquartered in Abbott Park, Illinois, that develops, manufactures and markets a broad portfolio of medical products and services. Founded in 1888, Abbott operates through multiple business areas that focus on diagnostics, medical devices, nutritionals and established pharmaceuticals. The company supplies hospitals, clinics, laboratories, retailers and direct-to-consumer channels with products intended to diagnose, treat and manage a wide range of health conditions.

In diagnostics, Abbott provides laboratory and point-of-care testing platforms and assays used to detect infectious diseases, chronic conditions and biomarkers; its Alinity family of instruments and rapid-test solutions are examples of this capability.